Kumar Prakash, Das Arijit, Chandra Satish, Gari Manju, Keshri U S P, Kumari Kusum
Department of Cardiology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, India.
Department of Pharmacology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, India.
Cardiol Res. 2016 Oct;7(5):173-177. doi: 10.14740/cr497w. Epub 2016 Nov 3.
Many epidemiological studies have established the relationship between hypertension and dyslipidemia. Calcium channel blockers (CCBs) are one of the first-line drugs for newly diagnosed patients with essential hypertension. Cilnidipine as a newer CCB acting by blocking both L- and N-type calcium channels possesses additional beneficial effects apart from lowering blood pressure (BP). The aim of this study was to evaluate the effectiveness of cilnidipine in patients with essential hypertension with borderline dyslipidemia and its effects on lipid profile.
Out of 45 enrolled patients, who fulfilled the inclusion criteria, only 37 completed the study. Cilnidipine was started at 10 mg/day, and then adjusted to 5 - 20 mg/day to achieve the target blood pressure.
After 12 weeks of study, patients showed significant reduction in systolic blood pressure, diastolic blood pressure, mean BP, heart rate and serum triglyceride level from baseline values (P < 0.00).
In clinical setting where both hypertension and hypertriglyceridemia exist, cilnidipine can be a promising drug of choice.
许多流行病学研究已证实高血压与血脂异常之间的关系。钙通道阻滞剂（CCB）是新诊断的原发性高血压患者的一线药物之一。西尼地平作为一种新型CCB，通过阻断L型和N型钙通道发挥作用，除了降低血压外还具有其他有益作用。本研究旨在评估西尼地平对原发性高血压合并边缘性血脂异常患者的有效性及其对血脂谱的影响。
45名符合纳入标准的入组患者中，只有37名完成了研究。西尼地平起始剂量为10毫克/天，然后调整至5 - 20毫克/天以达到目标血压。
经过12周的研究，患者的收缩压、舒张压、平均血压、心率和血清甘油三酯水平较基线值显著降低（P < 0.00）。
在高血压和高甘油三酯血症并存的临床情况下，西尼地平可能是一种有前景的选择药物。
